A monoclonal antibody targeting BLyS (Belimumab) is approved for treatment of highly active, autoantibody-positive systemic lupus erythematosus (SLE) despite standard treatment (14). The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.